COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure (PIE-I)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01411735
Recruitment Status : Completed
First Posted : August 8, 2011
Last Update Posted : November 6, 2017
Information provided by (Responsible Party):
Wake Forest University Health Sciences ( Wake Forest University )

Brief Summary:

BACKGROUND: Exercise intolerance is the primary symptom in older patients with heart failure and preserved ejection fraction (HFPEF), however little is known regarding its mechanisms and therapy.

METHODS: 71 elderly stable, compensated HFPEF patients (age 70+1 years; 80% women) with controlled blood pressure were randomized into a 12 month follow-up (FU) double-blind trial of enalapril 20 mg per day (E) vs. placebo (P). Assessments included: peak exercise oxygen consumption (VO2); six-minute walk test; Minnesota Living with HF Questionnaire (MLHF); MRI; Doppler-echocardiography; and vascular ultrasound.

Condition or disease Intervention/treatment Phase
Heart Failure With Preserved Ejection Fraction Heart Failure, Congestive Drug: Enalapril Drug: placebo Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 71 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)
Primary Purpose: Treatment
Official Title: Evaluation of Enalapril Versus Placebo in Patients With Diastolic Heart Failure
Study Start Date : July 2003
Actual Primary Completion Date : June 2004
Actual Study Completion Date : July 2008

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Heart Failure

Arm Intervention/treatment
Active Comparator: Enalapril
2.5mg titrated up to 10mg- twice daily
Drug: Enalapril
2.5mg titrated up to 10mg twice daily

Placebo Comparator: placebo
2.5 mg titrate up to 10mg twice daily placebo comparator
Drug: placebo
2.5mg titrated up to 10mg twice daily.

Primary Outcome Measures :
  1. exercise capacity and aortic distensibility [ Time Frame: 9 months ]
    MRI and expired gas analysis

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   60 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • All participants will be 60 years of age or older.

Exclusion Criteria:

  1. systolic dysfunction
  2. patients with evidence of significant ischemic or valvular heart disease
  3. chronic pulmonary disease.

Participants who appear preliminarily eligible are invited to a formal screening visiting with an investigator cardiology physician. They also undergoing a rest and exercise electrocardiogram and echocardiogram and pulmonary function testing as well as blood hematology and chemistry tests.

Final eligibility will be based upon all information available at the conclusion of the screening visits test, including hospital and outpatient records, history, physical examination, echocardiogram and exercise test.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01411735

Sponsors and Collaborators
Wake Forest University
Layout table for investigator information
Principal Investigator: Dalane W Kitzman, MD Professor of Medicine-Cardiology Section
Layout table for additonal information
Responsible Party: Wake Forest University Identifier: NCT01411735    
Other Study ID Numbers: R01AG018915-01 ( U.S. NIH Grant/Contract )
First Posted: August 8, 2011    Key Record Dates
Last Update Posted: November 6, 2017
Last Verified: August 2011
Additional relevant MeSH terms:
Layout table for MeSH terms
Heart Failure
Heart Failure, Diastolic
Heart Diseases
Cardiovascular Diseases
Angiotensin-Converting Enzyme Inhibitors
Protease Inhibitors
Enzyme Inhibitors
Molecular Mechanisms of Pharmacological Action
Antihypertensive Agents